RT Journal Article
T1 Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain.
A1 Alcázar-Navarrete, Bernardino
A1 García-Rio, Francisco
A1 Sánchez, Guadalupe
A1 Mariscal, Esther
A1 García, Andrea
A1 Cuesta, Maribel
A1 Uría, Estefany
A1 Miravitlles, Marc
K1 COPD
K1 cost
K1 eosinophil
K1 frequent exacerbation
K1 health care resources
K1 triple therapy
AB The cost of chronic obstructive pulmonary disease (COPD) in Spain has been studied from different perspectives, but parameters such as the patient's phenotype have seldom been considered. Our aim was to describe the disease burden of COPD patients with frequent exacerbator phenotype, treated with triple therapy. An observational, multicenter study was carried out from December 2017 to November 2018 in pulmonology services among patients ≥40 years with COPD confirmed diagnosis receiving triple therapy (ICS/LAMA/LABA) and history of ≥2 moderate or ≥1 severe exacerbation in the 12 months prior to the inclusion visit. COPD-related healthcare resources were collected over a 12-months period prior to the inclusion visit: pharmacological and non-pharmacological treatments, medical and ER visits, hospitalizations, tests and productivity loss. Costs were updated to €2019. Patients were classified according to blood eosinophil levels:  A total of 306 patients were included (77.1% men), with mean age of 69.9 years. Mean COPD exacerbation rate was 2.5/patient/year and 51.3% of patients had ≥150 cells/µL eosinophil level. On average, for the total population, COPD-related visits/patients/year were 6.2. Resource use in moderate exacerbation was higher in patients with eosinophils ≥150 cells/µL, whereas in severe exacerbation was higher in patients with eosinophils  The impact of exacerbating COPD patients treated with triple therapy in Spain is large, especially among those with eosinophils
YR 2021
FD 2021-07-21
LK http://hdl.handle.net/10668/18270
UL http://hdl.handle.net/10668/18270
LA en
DS RISalud
RD Apr 11, 2025